NEPA, a new fixed combination of netupitant and palonosetron, is a cost-effective intervention for the prevention of chemotherapy-induced nausea and vomiting in the UK

• Hauptverfasser: Helene Cawston (Verfasst von), Francois Bourhis (Verfasst von), Jennifer Eriksson (Verfasst von), Pierfrancesco Ruffo (Verfasst von), Paolo D'Agostino (Verfasst von), Marco Turini (Verfasst von), Lee Schwartzberg (Verfasst von), Alistair McGuire (Verfasst von)
• Format: Buch
• Veröffentlicht: BioExcel Publishing Ltd, 2017-03-01T00:00:00Z.
• Schlagworte: article
• Online-Zugang: Connect to this object online.

Background: The objective was to evaluate the cost-effectiveness of NEPA, an oral fixed combination netupitant (NETU, 300 mg) and palonosetron (PA, 0.5 mg) compared with aprepitant and palonosetron (APPA) or palonosetron (PA) alone, to prevent chemotherapy-induced nausea and vomiting (CINV) in patie...